UPB - NASDAQ

Upstream Bio, Inc.

UPB·NASDAQ

$20.97

-5.9%

HealthcareBiotechnology

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.13B

EPS-0.7400

P/E Ratio-3.69

Earnings Date11/06/2025

-59.17M

Operating Cash Flow

56%

3Y+211.0%

5Y+211.0%

10Y+211.0%

-59.48M

Investing Cash Flow

-28%

3Y+72443.0%

5Y+72443.0%

10Y+72443.0%

418.91M

Financing Cash Flow

223%

3Y+4105.0%

5Y+4105.0%

10Y+4105.0%

Upstream Bio, Inc. Cash Conversion Engine

UPB · NASDAQ

FCF Components

Net Income-62.81M

Depreciation & Amortization89.00K

Stock-Based Compensation6.00M

Change in Working Capital1.87M

Others-4.33M

Capital Expenditures-511.00K

Free Cash Flow-59.68M

Cash Flow Quality Analysis

FCF Conversion Rate

95.0%

Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.

CapEx Intensity

-1.3%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

-56.8%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$1.87M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Upstream Bio, Inc. Cash Flow Statement

UPB • NASDAQ

Upstream Bio, Inc. Cash Flow Statement	Dec 2024	Dec 2023	Dec 2022
OPERATING ACTIVITIES
Net Income	-62.8M	-20.5M	-23.9M
Depreciation & Amortization	89K	60K	7K
Stock-Based Compensation	6M	3.4M	1.3M
Other Non-Cash Items	-4.3M	-16.6M	149K
Change in Working Capital	1.9M	-4.3M	3.4M
Cash from Operating Activities	-59.2M	-37.9M	-19M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment	-511K	-144K	-82K
Purchase of Investments	-290.6M	-129M	(0.0)
Sale/Maturity of Investments	231.6M	46.3M	0.0
Cash from Investing Activities	-59.5M	-82.8M	-82K
FINANCING ACTIVITIES
Net Issuance of Common Stock	272.7M	0.0	0.0
Other Financing Items	-3.7M	118K	-37K
Cash from Financing Activities	418.9M	129.6M	10M
CASH FLOW SUMMARY
Net Change in Cash	300.3M	8.8M	-9.1M
Cash at Beginning of Period	25.8M	17.1M	26.2M
Cash at End of Period	326.1M	25.8M	17.1M
Free Cash Flow	-59.7M	-38.1M	-19.1M

SEC Filings

UPB - Filing history and reports

No SEC filings available for UPB

Related Guides

Blog Categories

Continue your UPB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.